Start here if you're new
what it is
Halozyme helps other drugmakers give medicines by injection and collects money when those partnered drugs sell.
how it gets paid
Last year Halozyme Therapeutic made $1.4B in revenue.
why it's growing
Revenue grew 37.6% last year. Revenue rose 167% from a year earlier, and EPS jumped 157%.
what just happened
Halozyme posted $945M of revenue and $3.68 EPS in the quarter.
At a glance
B+ balance sheet — decent shape, but not bulletproof
30/100 earnings predictability — expect surprises
16.7x trailing p/e — the market's not buying it — or you found a deal
24.2% return on capital — every dollar works hard here
$3.43 fy2024 eps est
xvary composite: 55/100 — below average
What they do
Halozyme helps other drugmakers give medicines by injection and collects money when those partnered drugs sell.
You are not betting on patients. You are betting on 6 pharma partners. That is the whole trick. Return on capital → profit per dollar invested → 24.2% and operating margin → profit after operating costs → 33.6% say the deals still pay you after the lawyers, scientists, and paperwork.
How they make money
$1.4B
annual revenue · their business grew +37.6% last year
total revenue
$1.4B
+37.6%
The products that matter
drug delivery licensing platform
ENHANZE
$1.4B revenue base · 12+ partners
this platform underpins the entire $1.4B business on this page, and that scale came with a 62.3% operating margin. The appeal is simple: partners sell the drugs, Halozyme collects the economics.
royalty engine
partner commercial adoption
partner launches and royalties
+37.6% growth from last year
revenue grew 37.6% from last year, which tells you the platform is doing more than sitting in a patent folder. Your upside depends on partners selling more doses and adding more products.
growth lever
capital-light economics
high-margin model
24.2% return on capital
a 24.2% return on capital means this is not a cash-burning biotech science project. It is already a profitable platform business — the question is how durable that profit stream is.
quality check
Key numbers
$1.4B
annual revenue
That is a real business size, not a science project. Your company is already pulling in nine digits a year.
24.2%
return on capital
Return on capital means profit per dollar invested. 24.2% says management gets a strong payoff on each dollar tied up.
33.6%
operating margin
Operating margin means profit after running the business. 33.6% says more than a third of sales survives the machine.
$800M
long-term debt
Debt is the bill that arrives later. $800M is large enough to matter, but small enough to stay manageable at this scale.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 30 / 100
- long-term debt $800M (10% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for HALO right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Halozyme posted $945M of revenue and $3.68 EPS in the quarter.
Revenue rose 167% from a year earlier, and EPS jumped 157%. The quarter was powered by partner and milestone timing, which makes the top line lumpy.
$945M
revenue
$3.68
eps
167%
revenue vs. last year
revenue growth
167% vs. prior year revenue growth is the number that matters. It says the partner model is throwing off cash fast.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
HALO's biggest risk is partner-dependent ENHANZE royalties. This is a high-margin business, but it is still a high-dependence business.
med
partner concentration without segment disclosure
This page shows one revenue line: $1.4B total revenue. It does not show how much comes from any single partner or product. When your model depends on 12+ pharma partners, concentration matters a lot.
If one large partner slows, the effect can hit a meaningful chunk of the $1.4B revenue base before you have time to re-rate the story.
med
earnings visibility is weaker than the margin profile suggests
Earnings predictability is 30/100. In human terms: the business is profitable, but quarter-to-quarter expectations can still wobble.
That combination can create fast drawdowns. A stock at 16.7x earnings near its 52-week high has less patience for messy prints than a stock already left for dead.
med
regulatory friction at partners can slow Halozyme anyway
The moat is partly regulatory stickiness, but that cuts both ways. When partners need approvals, reformulations, or label changes, HALO waits with them.
Because the model is royalty-based, delays do not just defer growth stories. They can push out cash tied to commercial dosing.
If royalty revenue stays above $1B and the 6-partner base holds, the risk picture stays manageable.
source: institutional data · regulatory filings · risk analysis
Pay attention to
next report
does revenue stay on the current trajectory
$1.4B revenue and +37.6% growth set a high bar. If the next update comes in softer, the stock does not have much room to shrug it off at $79.44.
margin
can the 62.3% operating margin hold
That is the most unusual number on the page. If it starts slipping, the market may stop treating HALO like a royalty platform and start treating it like a normal biotech.
valuation
cheap multiple or fair warning
A 16.7x trailing p/e looks restrained next to the growth and margins. The catch is the 30/100 predictability score. One says opportunity. The other says caution.
balance sheet
debt is manageable until the business gets less smooth
$800M of long-term debt is 10% of capital, which is reasonable. It stays reasonable as long as partner royalties keep arriving on schedule.
Analyst rankings
earnings predictability
30 / 100
in human-speak, analysts think the business can still surprise you even with strong underlying margins.
risk rank
3
middle-of-the-pack safety. Safer than many biotech names, less stable than true defensive compounders.
xvary composite
55 / 100
the quality of the business is doing a lot of work. The setup around it is less forgiving.
source: institutional data
Institutional activity
institutional ownership data for HALO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$79
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive